Academic partners can receive broad access to MorphoSys’s Ylanthia technology to validate their portfolio of novel disease-related targets and generate therapeutic antibody candidates against them. In return, MorphoSys would receive the option to in-license and develop individual programs resulting from this work. Exciting new drug candidates may emerge from these partnerships, adding valuable assets to our pipeline. Recent alliances in this field include agreements with Temple University’s Moulder Center for Drug Discovery Research. MorphoSys’s ability to turn an in-licensed target into a valuable commercial opportunity for its academic collaborator and its shareholders is exemplified by the MOR103 program. Starting from an exclusive license and collaboration agreement with Melbourne University, the program was advanced by MorphoSys into phase 2 clinical development. Based on very promising proof-of-concept data, MorphoSys secured GlaxoSmithKline as a partner to bring the compound to the market globally.
Various biopharmaceutical companies such as Galapagos and Merck have decided to engage in even more comprehensive alliances with MorphoSys. These partnerships start with joint target validation and antibody generation at MorphoSys and result in drug programs that are co-developed into the clinic and potentially beyond. If beneficial for a potential partner, collaboration agreements can be further enhanced with an investment by MorphoSys as part of our Innovation Capital initiative.